BBNX
Beta Bionics Inc
$
15.100
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
15.240
Open
14.370
VWAP
14.66
Vol
1.09M
Mkt Cap
--
Low
14.130
Amount
16.02M
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Show More
8 Analyst Rating
50.66% Upside
Wall Street analysts forecast BBNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBNX is 22.75 USD with a low forecast of 17.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
2 Hold
0 Sell
Strong Buy
50.66% Upside
Current: 15.100
Low
17.00
Averages
22.75
High
30.00
50.66% Upside
Current: 15.100
Low
17.00
Averages
22.75
High
30.00
Baird
Neutral
maintain
$15 -> $17
2025-07-30
Reason
Baird
Price Target
$15 -> $17
2025-07-30
maintain
Neutral
Reason
Baird raised the firm's price target on Beta Bionics to $17 from $15 and keeps a Neutral rating on the shares. The firm updated its model following solid Q2 results but being left with remaining higher uncertainties.
Truist
Richard Newitter
Buy
maintain
$18 -> $21
2025-07-30
Reason
Truist
Richard Newitter
Price Target
$18 -> $21
2025-07-30
maintain
Buy
Reason
Truist analyst Richard Newitter raised the firm's price target on Beta Bionics to $21 from $18 and keeps a Buy rating on the shares. The stock should see strength and could regain some recently lost ground following a solid Q2 revenue and EPS beat driven by new patient start upside, the analyst tells investors in a research note. An accelerating pharmacy channel shift has even bigger positive out-year estimate implications, the firm added.
Truist
Buy
initiated
$26
2025-06-17
Reason
Truist
Price Target
$26
2025-06-17
initiated
Buy
Reason
Truist initiated coverage of Beta Bionics with a Buy rating and $26 price target. Beta Bionics is the newest U.S. pump entrant with an algorithm focusing on ease-of-use and simpler setup for both patients and clinicians with competitive outcomes, and the firm's physician feedback suggests iLet and Beta Bionics' focuses align with unmet needs around automation, reduced setup, and future glucagon/insulin delivery, the analyst tells investors in a research note. The firm sees Beta Bionics increasing U.S. share to 5%-6% by 2028 within a $3B U.S. pump market and fueling a 37%+ 2024-2028 revenue compound annual growth rate.
Lake Street
NULL
to
Buy
initiated
$30
2025-06-12
Reason
Lake Street
Price Target
$30
2025-06-12
initiated
NULL
to
Buy
Reason
Lake Street assumed coverage of Beta Bionics with a Buy rating and $30 price target. The company has architected a best-in-class offering, optimal delivery channel, and R&D strategy supportive of long-term growth, according to the analyst, who does not think investors are ascribing enough value to the whole company strategy or the iLet's "best-in-class" user simplicity and patient outcomes that "presents a one-size-fits-all 'goldilocks' proposition for Type 1s and Type 2s."
Wolfe Research
Outperform
initiated
$20
2025-05-30
Reason
Wolfe Research
Price Target
$20
2025-05-30
initiated
Outperform
Reason
Wolfe Research last night initiated coverage of Beta Bionics with an Outperform rating and $20 price target. Insulin pumps are a double-digit growth category and Beta from a low base is taking share, the analyst tells investors in a research note. The firm says the company's revenue in the U.S. pump market has grown low-to-mid-teens over the last three years. Wolfe believes Beta Bionics' "differentiated" user experience and pharmacy preferred access strategy support continuation of faster than category-growth.
Wolfe Research
Mike Polark
Outperform
initiated
$20
2025-05-29
Reason
Wolfe Research
Mike Polark
Price Target
$20
2025-05-29
initiated
Outperform
Reason
Wolfe Research analyst Mike Polark initiated coverage of Beta Bionics with an Outperform rating and $20 price target.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Beta Bionics Inc (BBNX.O) is -7.49, compared to its 5-year average forward P/E of -6.76. For a more detailed relative valuation and DCF analysis to assess Beta Bionics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-6.76
Current PE
-7.49
Overvalued PE
-4.74
Undervalued PE
-8.78
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-8.50
Current EV/EBITDA
-5.33
Overvalued EV/EBITDA
-4.08
Undervalued EV/EBITDA
-12.92
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
7.06
Current PS
6.75
Overvalued PS
9.52
Undervalued PS
4.60
Financials
Annual
Quarterly
FY2024Q4
YoY :
+144.79%
20.44M
Total Revenue
FY2024Q4
YoY :
+55.81%
-13.04M
Operating Profit
FY2024Q4
YoY :
-3.93%
-18.11M
Net Income after Tax
FY2024Q4
YoY :
-4.55%
-0.42
EPS - Diluted
FY2024Q4
YoY :
+122.82%
-14.84M
Free Cash Flow
FY2024Q4
YoY :
-5.66%
57.19
Gross Profit Margin - %
FY2024Q4
YoY :
-71.03%
-79.34
FCF Margin - %
FY2024Q4
YoY :
-60.75%
-88.59
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
5
9.5M
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
BBNX News & Events
Events Timeline
2025-07-29 (ET)
2025-07-29
16:11:31
Beta Bionics raises FY25 revenue view to $88M-$93M from $82M-$87M
2025-07-29
16:10:27
Beta Bionics reports Q2 EPS (39c), consensus (47c)
2025-07-01 (ET)
2025-07-01
10:17:40
Wells says CBP proposal for CGMs expected, insulin pumps inclusion 'a surprise'
Sign Up For More Events
Sign Up For More Events
News
8.5
08-08ReutersBain Capital-backed Heartflow valued at $2.27 billion in solid Nasdaq debut
8.5
08-06ReutersBain Capital-backed Heartflow eyes $1.5 billion valuation in upsized US IPO
9.5
07-31NewsfilterBeta Bionics, Inc. (BBNX) Q2 2025 Earnings Call Transcript
Sign Up For More News
People Also Watch
MSFT
Microsoft Corp
520.580
USD
-1.64%
WMT
Walmart Inc
100.990
USD
-2.54%
XOM
Exxon Mobil Corp
107.600
USD
+1.39%
AVGO
Broadcom Inc
309.090
USD
-1.20%
NVDA
NVIDIA Corp
181.590
USD
-0.86%
META
Meta Platforms Inc
780.080
USD
-1.26%
AMZN
Amazon.com Inc
224.560
USD
+1.40%
AAPL
Apple Inc
233.330
USD
+1.60%
ORCL
Oracle Corp
244.180
USD
-3.81%
TSLA
Tesla Inc
339.380
USD
-0.43%
FAQ
What is Beta Bionics Inc (BBNX) stock price today?
The current price of BBNX is 15.1 USD — it has increased 6.19 % in the last trading day.
What is Beta Bionics Inc (BBNX)'s business?
What is the price predicton of BBNX Stock?
What is Beta Bionics Inc (BBNX)'s revenue for the last quarter?
What is Beta Bionics Inc (BBNX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Beta Bionics Inc (BBNX)'s fundamentals?
How many employees does Beta Bionics Inc (BBNX). have?